Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NewAmsterdam Pharma Company ( (NAMS) ) has shared an announcement.
On January 9, 2026, NewAmsterdam Pharma highlighted its 2025 clinical and regulatory progress for obicetrapib and set out key goals for 2026, underscoring its push toward commercialization in cardiovascular disease and potential expansion into neurodegeneration. In 2025, the company reported statistically significant reductions in Alzheimer’s disease biomarker p-tau217 from the Phase 3 BROADWAY trial, presented pooled Phase 3 efficacy and safety data for obicetrapib at major cardiology forums, and secured EMA validation of marketing applications for obicetrapib monotherapy and an obicetrapib/ezetimibe fixed-dose combination in hypercholesterolemia, with a European approval decision anticipated in the second half of 2026. Operationally, NewAmsterdam advanced three Phase 3 programs—PREVAIL, REMBRANDT and RUBENS—completed PREVAIL enrollment at over 9,500 patients, began RUBENS enrollment in December 2025, and plans to launch a dedicated early Alzheimer’s disease trial in 2026, leveraging emerging links between CETP inhibition and neurodegeneration. With approximately $729 million in unaudited cash, cash equivalents and marketable securities at year-end 2025, the company expects to be funded through the PREVAIL cardiovascular outcomes readout and a potential subsequent U.S. commercial launch, positioning it as a significant emerging player in the crowded LDL-C–lowering market and offering potential upside for partners and future shareholders if pivotal data and regulatory reviews are favorable.
The most recent analyst rating on (NAMS) stock is a Buy with a $45.00 price target. To see the full list of analyst forecasts on NewAmsterdam Pharma Company stock, see the NAMS Stock Forecast page.
Spark’s Take on NAMS Stock
According to Spark, TipRanks’ AI Analyst, NAMS is a Neutral.
The stock score is primarily influenced by the company’s strong technical performance, indicating positive market momentum. However, financial performance is a concern due to ongoing operational losses and negative cash flows, typical of biotech firms in early stages. Valuation is challenging due to negative earnings, but the company’s ability to raise capital provides some stability.
To see Spark’s full report on NAMS stock, click here.
More about NewAmsterdam Pharma Company
NewAmsterdam Pharma Company N.V. is a late-stage clinical biopharmaceutical company focused on developing oral, non-statin, low-density lipoprotein cholesterol (LDL-C)–lowering therapies for patients at risk of cardiovascular disease whose cholesterol is not adequately controlled or who cannot tolerate existing treatments. Its lead candidate, obicetrapib, a once-daily, low-dose, highly selective CETP inhibitor, is being advanced both as monotherapy and in a fixed-dose combination with ezetimibe, with European commercialization rights licensed to Italy-based Menarini Group.
Average Trading Volume: 1,084,701
Technical Sentiment Signal: Buy
Current Market Cap: $4.02B
See more insights into NAMS stock on TipRanks’ Stock Analysis page.